Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy.

Author: AllsupT, ChernW H, GarnettW R, HubbellJ, LaiA A, PellockJ M, RamsayR E, SanchezR M, ValakasA M, WarginW A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Lamotrigine, an antiepileptic drug, showed linear pharmacokinetics and did not induce its own metabolism in 11 patients on stable antiepileptic drug regimens. No significant medical, neurological, or hematological changes were observed, and no subjective effects were detected.
Paper Details　
Original Abstract of the Article :
In a double-blind parallel study, patients with epilepsy on stable regimen of antiepileptic drugs (AEDs) were given lamotrigine (8 pts) or placebo (3 pts). Patients were sequentially dosed with 100, 200 and 300 mg/day given as a b.i.d. regimen. After steady state was achieved, timed plasma lamotrigi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0920-1211(91)90012-5

データ提供：米国国立医学図書館（NLM）

Lamotrigine: A New Oasis in the Desert of Epilepsy Treatment

The treatment of [epilepsy] is an ongoing journey, and the search for effective and safe medications is a constant pursuit. This study examines the [pharmacokinetics] and safety of [lamotrigine (Lamictal)] in patients with epilepsy.

The researchers conducted a clinical trial to assess the pharmacokinetic properties of lamotrigine in patients with epilepsy. They found that lamotrigine was well-tolerated and had a predictable pharmacokinetic profile.

This research is like discovering a hidden oasis in the desert of epilepsy treatment, providing hope for patients who are seeking effective and safe medications.

Unlocking the Potential of Lamotrigine

The study suggests that lamotrigine has potential as an effective treatment for epilepsy.

It's like finding a new key that unlocks the door to a more manageable life for patients with epilepsy. This research could lead to better treatment options and improved quality of life for people living with epilepsy.

Health Impact: A Step Forward in Epilepsy Treatment

The study highlights the importance of continued research into new epilepsy medications.

It's like a beacon of hope shining in the desert, guiding us towards a future where epilepsy is more effectively managed. By exploring new treatment options, we can provide better care for those affected by this condition.

Dr. Camel's Conclusion

The study of lamotrigine for epilepsy treatment is a vital step in the ongoing journey to find effective solutions. It's like discovering a hidden well in the desert that provides clean and safe water for all. With continued research and development, we can create a brighter future for those affected by this disease.

Date :
  1. Date Completed 1992-07-15
  2. Date Revised 2019-09-12
Further Info :

Pubmed ID

1817959

DOI: Digital Object Identifier

10.1016/0920-1211(91)90012-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.